Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M6,799Revenue $M576Net Margin (%)-3.7Z-Score8.4
Enterprise Value $M6,453EPS $0.2Operating Margin %-5.2F-Score4
P/E(ttm))0Cash Flow Per Share $0.0Pre-tax Margin (%)-2.8Higher ROA y-yN
Price/Book5.010-y EBITDA Growth Rate %0Quick Ratio8.1Cash flow > EarningsY
Price/Sales11.15-y EBITDA Growth Rate %0Current Ratio8.7Lower Leverage y-yY
Price/Cash Flow725y-y EBITDA Growth Rate %-44.8ROA % (ttm)-1.1Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-1.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M145ROI % (ttm)-2.4Gross Margin Increase y-yN

Gurus Latest Trades with ALKS

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ALKSVanguard Health Care Fund 2014-06-30 Add0.13%$41.1 - $50.94
($46.06)
$ 45.58-1%Add 18.45%6,135,913
ALKSJohn Burbank 2014-06-30 Sold Out -0.01%$41.1 - $50.94
($46.06)
$ 45.58-1%Sold Out0
ALKSVanguard Health Care Fund 2014-03-31 Add0.19%$40.07 - $53.82
($47.32)
$ 45.58-4%Add 41.07%5,180,238
ALKSJohn Burbank 2014-03-31 Buy 0.01%$40.07 - $53.82
($47.41)
$ 45.58-4%New holding, 4651 sh.4,651
ALKSVanguard Health Care Fund 2013-12-31 Add0.1%$30.17 - $41.12
($36.93)
$ 45.5823%Add 28.18%3,672,087
ALKSVanguard Health Care Fund 2013-09-30 Add0.07%$28.66 - $35.35
($32.58)
$ 45.5840%Add 26.21%2,864,896
ALKSJoel Greenblatt 2013-09-30 Sold Out -0.03%$28.66 - $35.35
($32.58)
$ 45.5840%Sold Out0
ALKSVanguard Health Care Fund 2013-06-30 Add0.11%$22.35 - $33.72
($29.15)
$ 45.5856%Add 84.09%2,269,902
ALKSJoel Greenblatt 2013-06-30 Buy 0.03%$22.35 - $33.72
($29.15)
$ 45.5856%New holding, 26624 sh.26,624
ALKSVanguard Health Care Fund 2013-03-31 Add0.04%$18.52 - $23.81
($21.87)
$ 45.58108%Add 47.24%1,233,024
ALKSVanguard Health Care Fund 2012-03-31 Buy 0.07%$16.14 - $19.5
($16.48)
$ 45.58177%New holding, 787900 sh.787,900
ALKSJohn Burbank 2012-03-31 Sold Out -0.23%$16.14 - $19.5
($16.48)
$ 45.58177%Sold Out0
ALKSDaniel Loeb 2010-06-30 Sold Out -0.92%$10.7 - $13.75
($12.33)
$ 45.58270%Sold Out0
ALKSDaniel Loeb 2010-03-31 Buy 0.92%$9.41 - $14.01
($11.62)
$ 45.58292%New holding, 1000000 sh.1,000,000
ALKSGeorge Soros 2010-03-31 Sold Out $9.41 - $14.01
($11.62)
$ 45.58292%Sold Out0
ALKSJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.41 - $14.01
($11.62)
$ 45.58292%Sold Out0
ALKSGeorge Soros 2009-12-31 Buy $7.58 - $9.88
($8.72)
$ 45.58423%New holding, 22800 sh.22,800
ALKSDaniel Loeb 2009-12-31 Sold Out -0.37%$7.58 - $9.88
($8.72)
$ 45.58423%Sold Out0
ALKSDaniel Loeb 2009-09-30 Buy 0.37%$8.75 - $11.65
($10.13)
$ 45.58350%New holding, 500000 sh.500,000
ALKSJean-Marie Eveillard 2009-09-30 Buy 0.01%$8.75 - $11.65
($10.13)
$ 45.58350%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ALKS is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ALKS Vanguard Health Care Fund 2014-06-306,135,9134.250.81+18.45%
ALKS John Burbank 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


ALKS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FRATES JAMES MSVP & CFO, Alkermes plc 2014-09-10Sell16,000$43.186.76view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2014-09-02Sell1,100$45.082.26view
BREYER ROBERT ADirector 2014-09-02Sell5,000$45.122.17view
MITCHELL PAUL JDirector 2014-09-02Sell1,000$45.122.17view
FRATES JAMES MSVP & CFO, Alkermes plc 2014-08-27Sell16,000$45.082.26view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2014-08-26Sell16,000$452.44view
FRATES JAMES MSVP & CFO, Alkermes plc 2014-08-13Sell15,000$41.3711.43view
Ehrich ElliotSVP, R&D & CMO, Alkermes, Inc. 2014-08-11Sell16,667$41.6510.68view
Pugh Gordon GSVP, COO & CRO, Alkermes, Inc. 2014-08-04Sell23,250$43.26.71view
BREYER ROBERT ADirector 2014-08-01Sell5,000$42.538.39view

Press Releases about ALKS :

    Quarterly/Annual Reports about ALKS:

    News about ALKS:

    Articles On GuruFocus.com
    wait for positive ea Apr 06 2013 
    comment on ALKS Mar 09 2013 
    Best Health Care Investor Edward Owens Buys One New Health Care Stock in First Quarter Apr 30 2012 
    Weekly CEO Sells Highlight: Herbalife, CNO Financial Group, Alkermes plc, and TransDigm Oct 08 2011 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 03 2011 
    Weekly Guru Bargains Highlights: SKX, VRX, ALKS, DF, SVU Dec 05 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Alkermes Inc. Reports Operating Results (10-K) May 21 2010 
    Alkermes Inc. Reports Operating Results (10-Q) Feb 04 2010 
    Opportunistic Coat-tailing Jan 05 2010 

    More From Other Websites
    Alkermes Completes Enrolment for Phase II ALKS 3831 Study Sep 04 2014
    Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel,... Sep 03 2014
    Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference Sep 02 2014
    Alkermes Begins a Study on ALKS7106 for Treatment of Pain Aug 27 2014
    Alkermes Gains on Aripiprazole Lauroxil NDA Submission Aug 26 2014
    Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain Aug 26 2014
    Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of... Aug 25 2014
    Wall Street Transcript Interview with Howard Zauberman, the President and CEO of Vision-Sciences,... Aug 08 2014
    Alkermes Reports Loss in Q2 on Higher Costs, Revenues Up Aug 04 2014
    Q2 2014 Alkermes plc Earnings Release - Before Market Open Jul 31 2014
    ALKERMES PLC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
    Alkermes plc Reports Second Quarter 2014 Financial Results Jul 31 2014
    Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major... Jul 30 2014
    Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results Jul 24 2014
    Alkermes' Pipeline Development Impresses, Key Updates Ahead Jul 21 2014
    Alkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS Jul 17 2014
    Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple... Jul 17 2014
    Alkermes Announces Notices of Allowance for U.S. Patents for Four CNS Pipeline Candidates Jul 09 2014
    Momentum names slammed as volatility comes back Jul 08 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK